Theriva Biologics (TOVX) Non-Current Assets (2010 - 2026)
Theriva Biologics (TOVX) posted quarterly Non-Current Assets of $21.5 million for Q1 2026, up 9.17% year-over-year from $19.7 million in Q1 2025, and up 3.46% quarter-over-quarter from $20.8 million in Q4 2025.
Theriva Biologics (TOVX) Non-Current Assets (2010 - 2026) Analysis & Trends
Theriva Biologics (TOVX) has reported Non-Current Assets for 17 consecutive years, with $21.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 9.17% year-over-year to $21.5 million; the TTM figure through Mar 2026 stood at $84.3 million (up 2.78% YoY), while the FY2025 annual figure was $20.8 million, up 8.92% from the prior year.
- Non-Current Assets rose to $21.5 million in Q1 2026 per TOVX's latest filing, from $20.8 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $29.4 million in Q1 2022 and bottomed at $19.1 million in Q4 2024.
- Historically, Non-Current Assets has averaged $24.1 million across 5 years, with a median of $24.4 million in 2022.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 6944.02% — and 2024, when it plunged 31.44%.
- Theriva Biologics' Non-Current Assets stood at $26.3 million in 2022, then advanced by 5.6% to $27.8 million in 2023, then sank by 31.44% to $19.1 million in 2024, then gained by 8.92% to $20.8 million in 2025, then climbed by 3.46% to $21.5 million in 2026.
- Business Quant data shows TOVX's Non-Current Assets at $21.5 million in Q1 2026, $20.8 million in Q4 2025, and $20.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 18.06 Bn |
| 10 | Theriva Biologics | 11.01 Mn | 11.01 Mn | - | 21.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 21.19 Mn |
| Mar 31, 2026 | 21.49 Mn |
| Dec 31, 2025 | 20.77 Mn |
| Sep 30, 2025 | 20.93 Mn |
| Jun 30, 2025 | 21.09 Mn |
| Mar 31, 2025 | 19.69 Mn |
| Dec 31, 2024 | 19.07 Mn |
| Sep 30, 2024 | 20.58 Mn |
| Jun 30, 2024 | 22.68 Mn |
| Mar 31, 2024 | 27.07 Mn |
| Dec 31, 2023 | 27.82 Mn |
| Sep 30, 2023 | 26.78 Mn |
| Jun 30, 2023 | 27.48 Mn |
| Mar 31, 2023 | 27.59 Mn |
| Dec 31, 2022 | 26.34 Mn |
| Sep 30, 2022 | 24.38 Mn |
| Jun 30, 2022 | 25.75 Mn |
| Mar 31, 2022 | 29.44 Mn |
| Dec 31, 2021 | 1.51 Mn |
| Sep 30, 2021 | 1.56 Mn |